应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AUPH Aurinia Pharmaceuticals Inc
未开盘 04-04 16:00:00 EDT
7.81
-0.24
-2.98%
盘后
7.67
-0.14
-1.81%
17:03 EDT
最高
7.98
最低
7.72
成交量
156.74万
今开
7.81
昨收
8.05
日振幅
3.23%
总市值
10.73亿
流通市值
10.42亿
总股本
1.37亿
成交额
1,226万
换手率
1.17%
流通股本
1.33亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期,销售额$59.87M低于$59.94M的预期
财报速递 · 02-27
Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期,销售额$59.87M低于$59.94M的预期
Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%
市场透视 · 2024-12-10
Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%
Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元,同比增加206.69%
市场透视 · 2024-11-16
Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元,同比增加206.69%
异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%
异动解读 · 2024-11-07
异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%
Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元
市场透视 · 2024-11-07
Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元
异动解读 | Aurinia Pharmaceuticals公司宣布重组计划 盘前股价大涨
异动解读 · 2024-11-07
异动解读 | Aurinia Pharmaceuticals公司宣布重组计划 盘前股价大涨
加载更多
公司概况
公司名称:
Aurinia Pharmaceuticals Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。
发行价格:
--
{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":7.81,"timestamp":1743796800000,"preClose":8.05,"halted":0,"volume":1567420,"hourTrading":{"tag":"盘后","latestPrice":7.6685,"preClose":7.81,"latestTime":"17:03 EDT","volume":19945,"amount":155750.21,"timestamp":1743800589848},"delay":0,"floatShares":133425499,"shares":137339016,"eps":0.04,"marketStatus":"未开盘","change":-0.24,"latestTime":"04-04 16:00:00 EDT","open":7.81,"high":7.98,"low":7.72,"amount":12258002.780772,"amplitude":0.032298,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.04,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":8.05,"preHourTrading":{"tag":"盘前","latestPrice":7.82,"preClose":8.05,"latestTime":"09:29 EDT","volume":3749,"amount":29563.772724399998,"timestamp":1743773386427},"postHourTrading":{"tag":"盘后","latestPrice":7.6685,"preClose":7.81,"latestTime":"17:03 EDT","volume":19945,"amount":155750.21,"timestamp":1743800589848},"volumeRatio":1.165159080852204,"impliedVol":0.417,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/AUPH","defaultTab":"news","newsList":[{"id":"1163649301","title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期,销售额$59.87M低于$59.94M的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1163649301","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163649301?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:05","pubTimestamp":1740654320,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals 报告称季度每股收益为$0.01,超过了分析师一致预期的$,超出150%。公司报告的季度销售额为$59.87百万,低于分析师一致预期的$59.94百万,差距为0.13%。与去年同期$45.09百万的销售额相比,这增加了32.76%。以上内容来自Benzinga Earnings专栏,原文如下:Aurinia Pharmaceuticals reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $ by 150 percent. This is a 105.26 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期,销售额$59.87M低于$59.94M的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2490115780","title":"Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490115780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490115780?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:32","pubTimestamp":1733841172,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时32分,Aurinia Pharmaceuticals Inc股票出现波动,股价大幅上涨5.59%。截至发稿,该股报9.64美元/股,成交量19.1063万股,换手率0.13%,振幅1.53%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.01%。其相关个股中,Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大,Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃,换手率分别为1717.09%、404.62%、88.15%,振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Psyence Biomedical Ltd.、Chimerix, Inc.,振幅分别为24.58%、21.74%、17.33%。Aurinia Pharmaceuticals Inc公司简介:Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2484924548","title":"Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元,同比增加206.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484924548?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772946,"startTime":"0","endTime":"0","summary":"11月17日,Aurinia Pharmaceuticals Inc公布财报,公告显示公司2024财年第三财季净利润为14.35百万美元,同比增加206.69%;其中营业收入为67.77百万美元,同比增加24.30%,每股基本收益为0.10美元。机构评级:截至2024年11月17日,当前有7家机构对Aurinia Pharmaceuticals Inc目标价做出预测,其中目标均价为10.84美元,其中最低目标价为8.00美元,最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH"],"gpt_icon":0},{"id":"1154738439","title":"异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154738439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154738439?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:49","pubTimestamp":1730990947,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc今日盘中大涨7.06%,引发了市场的广泛关注。公司宣布将进行大规模重组,包括裁员约28%的全职员工,优化临床开发项目组合,以及外包部分非核心职能等措施。重组过程中,Aurinia将继续专注于其主打产品Lupkynis的市场推广工作,并寻求与潜在战略合作伙伴的合作,以加速实现公司的商业目标。投资者对这一重组计划反映了积极态度,公司股价盘中大涨反映了市场对其未来发展前景的充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":0},{"id":"2481186028","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481186028?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:31","pubTimestamp":1730989875,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时31分,Aurinia Pharmaceuticals Inc股票出现波动,股价大幅拉升7.05%。截至发稿,该股报8.05美元/股,成交量10.3461万股,换手率0.07%,振幅0.00%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Ensysce Biosciences, Inc.、Mustang Bio, Inc.涨幅较大,Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃,换手率分别为76.92%、54.48%、47.54%,振幅较大的相关个股有Tuhura Biosciences, Inc.、Immunic, Inc.、Fennec Pharmaceuticals Inc.,振幅分别为8.54%、5.93%、4.85%。Aurinia Pharmaceuticals Inc公司简介:Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1163681819","title":"异动解读 | Aurinia Pharmaceuticals公司宣布重组计划 盘前股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1163681819","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163681819?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:26","pubTimestamp":1730989593,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc (股票代码:AUPH)今日盘前大涨6.65%,引发市场广泛关注。公司宣布将进行重组,包括裁员和优化运营,旨在降低运营成本、提高效率。\n\nAurinia表示,在当前经济环境下,为了确保公司长期可持续发展,必须采取一些艰难但关键的措施。此次重组计划预计可节省大约1.25亿美元的年度运营支出。\n\n重组的具体内容包括裁员约28%的全职员工,优化临床开发项目组合,外包部分非核心职能等。Aurinia还将继续专注于其主打产品Lupkynis的市场推广,并寻求战略性合作伙伴关系,以加速实现商业目标。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0579},{"period":"1month","weight":-0.0992},{"period":"3month","weight":-0.0855},{"period":"6month","weight":0.0969},{"period":"1year","weight":0.5344},{"period":"ytd","weight":-0.1303}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.086303},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00852},{"month":3,"riseRate":0.454545,"avgChangeRate":0.093863},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.01359},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004093},{"month":6,"riseRate":0.4,"avgChangeRate":-0.030211},{"month":7,"riseRate":0.6,"avgChangeRate":0.036556},{"month":8,"riseRate":0.5,"avgChangeRate":-0.045687},{"month":9,"riseRate":0.5,"avgChangeRate":0.078058},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035973},{"month":11,"riseRate":0.545455,"avgChangeRate":0.019351},{"month":12,"riseRate":0.454545,"avgChangeRate":0.102241}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}